PACB

#3014
Pacific Biosciences of California, Inc. - Common Stock
1.4 0 USD
-0.10%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
1.40
1.40
Intervallo Annuale
1.07
2.73
Variazione giornaliera
-9.68%
Variazione Mensile
-4.76%
Variazione di 6 mesi
-12.50%
Variazione Annuale
+7.69%
Chiusura Precedente
1.5 5
Open
1.4 0
Minimo
1.4 0
Massimo
1.4 0
Volume
53
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, Q1 FY2026
8-K

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. current report, 10 May 2021

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Pacific Biosciences of California, Inc. on May 10, 2021. The filing discloses the appointment of a new executive officer and the departure of the previous Chief Accounting Officer.

Key Financial Metrics

The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.

Material Changes

  • Appointment: Michele Farmer was appointed Vice President and Chief Accounting Officer, effective May 17, 2021.
  • Departure: Eric E. Schaefer, who served as Vice President and Chief Accounting Officer since May 26, 2020, was notified of his replacement on May 10, 2021.
  • Compensation Package for Michele Farmer:
    • Annual base salary: $295,000.
    • Relocation expenses: $75,000.
    • Target bonus: 40% of base salary.
    • Stock options: 80,000 shares under the 2020 Inducement Equity Incentive Plan (vesting 25% after one year, then monthly).
    • Restricted Stock Units (RSUs): 40,000 shares (vesting 25% annually).

Outlook, Risks, and Contingencies

Severance and Change in Control: Ms. Farmer is eligible for a severance agreement providing 6 months of base salary and COBRA coverage upon termination without cause or resignation for good reason. In the event of a change in control within 3 months prior to or 12 months following the event, benefits increase to 9 months of salary, pro-rated bonus, and 100% acceleration of unvested equity awards.

Risks: The filing notes no family relationships or undisclosed transactions involving the new appointee.

Investor Verification Checklist

  • Verify the exact start date of Michele Farmer's employment (May 17, 2021) and the transition timeline for Eric E. Schaefer.
  • Confirm the total equity grant value based on the fair market value of the stock on the grant date.
  • Review the specific performance goals required to achieve the 40% target bonus.
  • Assess the impact of the new Chief Accounting Officer's background (formerly Illumina) on the company's financial reporting standards.

Notizie